西妥昔单抗联合化疗用于晚期头颈部鳞癌的成本-效果分析

Cost-effectiveness analysis of cetuximab in combination with chemotherapy for advanced head and neck squamous cell cancer

目的研究西妥昔单抗联合化疗用于晚期头颈部鳞癌患者的成本效果性。方法根据EXTREM E临床试验数据,结合我国医疗费用及消费水平,进行成本-效果分析,并对结果进行敏感度分析。结果西妥昔单抗联合化疗方案相较于单纯化疗方案,每例患者总生存期增加1个月,需多花费50 327.0元人民币。结论西妥昔单抗联合化疗方案相对于单纯化疗方案不具有成本效果优势。

Objective To compare the cost-effectiveness of cetuximab in combination with chemotherapy ver-sus chemotherapy alone for advanced head and neck squamous cell cancer. Methods According to EXTREME clinical trial data,cost-effectiveness and sensitivity analysis of the results was conducted based on domestic costs and consump-tion levels. Results Cetuximab in combination with chemotherapy regimen could prolong one month of overall surviv-al with additional cost of 50 327.0 yuan in each case compared to chemotherapy alone regimen. Conclusion Cetux-imab in combination with chemotherapy does not suggest better cost effectiveness compared to chemotherapy alone.